Abstract | OBJECTIVE: STUDY DESIGN: A double-blind, randomized, controlled clinical trial was carried out at King Chulalongkorn Memorial Hospital. Sixty cases of CHM classified as high risk were recruited and randomly allocated to a chemoprophylactic or control group. Within one week after evacuation of molar tissues, actinomycin D was administered in the chemoprophylactic group. Patients in the control group were given only intravenous fluid and analgesic drugs. The number of patients with malignant sequelae who required therapeutic chemotherapy after evacuation of hydatidiform mole in each group was recorded. RESULTS: CONCLUSION: One course of actinomycin D given as chemoprophylaxis decreased by 72.4% malignant sequelae after evacuation of molar tissue in patients with high-risk CHM. This may be particularly beneficial in patients with high-risk CHM who cannot be followed closely, whose compliance is in question and for whom hormonal follow-up is not available or unreliable.
|
Authors | S Limpongsanurak |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 46
Issue 2
Pg. 110-6
(Feb 2001)
ISSN: 0024-7758 [Print] United States |
PMID | 11255809
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Dactinomycin
|
Topics |
- Adolescent
- Adult
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Chemotherapy, Adjuvant
- Dactinomycin
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Hydatidiform Mole
(complications, prevention & control, surgery)
- Incidence
- Pregnancy
- Risk Factors
- Uterine Neoplasms
(complications, prevention & control, surgery)
|